Altimmune has announced it expects to produce topline data from its phase 2 RECLAIM study of pemvidutide in alcohol use disorder. ALT is planning to start a large phase 3 of pemvidutide in MASH in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results